
Ching-Lung Lai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5232674/publications.pdf Version: 2024-02-01



CHINC-LUNC LAL

#	Article	IF	CITATIONS
1	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International, 2016, 10, 1-98.	1.9	1,908
2	A One-Year Trial of Lamivudine for Chronic Hepatitis B. New England Journal of Medicine, 1998, 339, 61-68.	13.9	1,773
3	Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. New England Journal of Medicine, 2006, 354, 1011-1020.	13.9	1,118
4	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. New England Journal of Medicine, 2015, 373, 2599-2607.	13.9	945
5	Viral hepatitis B. Lancet, The, 2003, 362, 2089-2094.	6.3	929
6	Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology, 2010, 52, 886-893.	3.6	840
7	Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. New England Journal of Medicine, 2007, 357, 2576-2588.	13.9	735
8	Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003, 125, 1714-1722.	0.6	724
9	Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B. Clinical Infectious Diseases, 2003, 36, 687-696.	2.9	604
10	Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin Use. New England Journal of Medicine, 2002, 346, 2033-2038.	13.9	578
11	Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology, 2001, 33, 1527-1532.	3.6	565
12	Adult-to-Adult Living Donor Liver Transplantation Using Extended Right Lobe Grafts. Annals of Surgery, 1997, 226, 261-270.	2.1	523
13	Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. Journal of Hepatology, 2009, 50, 80-88.	1.8	517
14	Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2010, 51, 422-430.	3.6	515
15	Hepatitis B virus infection. Nature Reviews Disease Primers, 2018, 4, 18035.	18.1	490
16	Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology, 2000, 31, 330-335.	3.6	408
17	A comparison of fibrosis progression in chronic liver diseases. Journal of Hepatology, 2003, 38, 257-265.	1.8	401
18	Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut and Liver, 2016, 10, 332-9.	1.4	399

#	Article	IF	CITATIONS
19	A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B. Gastroenterology, 2005, 129, 528-536.	0.6	380
20	HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 1192-1199.	0.6	370
21	Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer, 1988, 62, 479-483.	2.0	356
22	Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology, 2001, 34, 785-791.	3.6	354
23	SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases. Hepatology, 2004, 39, 302-310.	3.6	352
24	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Science Translational Medicine, 2017, 9, .	5.8	343
25	A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B. Gastroenterology, 2005, 129, 528-536.	0.6	338
26	Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology, 1987, 92, 1839-1843.	0.6	320
27	Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut, 2005, 54, 1610-1614.	6.1	317
28	Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 2002, 123, 1831-1838.	0.6	286
29	Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. Journal of Clinical Oncology, 2014, 32, 3736-3743.	0.8	283
30	Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology, 2002, 36, 186-194.	3.6	274
31	Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Journal of Hepatology, 1990, 10, 29-34.	1.8	245
32	A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology, 1992, 102, 2091-2097.	0.6	241
33	Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. Liver Transplantation, 2007, 13, 349-360.	1.3	239
34	Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology, 2000, 31, 201-206.	3.6	230
35	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease. Antiviral Therapy, 2007, 12, 1295-1304.	0.6	230
36	Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1276-1282.	1.4	227

#	Article	IF	CITATIONS
37	A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer, 2002, 94, 1747-1752.	2.0	222
38	HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. Hepatology, 2004, 39, 1694-1701.	3.6	222
39	Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology, 1993, 17, 389-394.	3.6	220
40	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Research, 2015, 121, 47-58.	1.9	216
41	Long-term follow-up of interferon alfa treatment in chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology, 2001, 34, 139-145.	3.6	207
42	Natural history of hepatitis-related hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1652.	1.4	203
43	Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology, 2003, 38, 1419-1427.	3.6	190
44	Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation. Gastroenterology, 2011, 141, 1212-1219.	0.6	190
45	A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive chinese children. Hepatology, 1988, 8, 1130-1133.	3.6	189
46	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut, 2015, 64, 667-672.	6.1	185
47	α-fetoprotein monitoring in chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma. Hepatology, 1989, 9, 110-115.	3.6	183
48	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology, 2013, 57, 399-408.	3.6	183
49	Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis with Telbivudine or Adefovir. Annals of Internal Medicine, 2007, 147, 745.	2.0	175
50	Recurrence of Hepatitis B-Related Hepatocellular Carcinoma Is Associated With High Viral Load at the Time of Resection. American Journal of Gastroenterology, 2008, 103, 1663-1673.	0.2	175
51	LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION. Lancet, The, 1988, 332, 298-302.	6.3	169
52	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. Journal of Antimicrobial Chemotherapy, 2011, 66, 2715-2725.	1.3	168
53	PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN. Lancet, The, 1987, 330, 877-880.	6.3	164
54	The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. Annals of Internal Medicine, 2007, 147, 58.	2.0	163

#	Article	IF	CITATIONS
55	Review article: hepatitis B coreâ€related antigen (<scp>HB</scp> crAg): an emerging marker for chronic hepatitis B virus infection. Alimentary Pharmacology and Therapeutics, 2018, 47, 43-54.	1.9	161
56	A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology, 2002, 36, 687-691.	3.6	157
57	Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut, 2007, 57, 98-102.	6.1	154
58	MINIMUM GRAFT VOLUME FOR SUCCESSFUL ADULT-TO-ADULT LIVING DONOR LIVER TRANSPLANTATION FOR FULMINANT HEPATIC FAILURE. Transplantation, 1996, 62, 696-698.	0.5	151
59	Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. Hepatology, 1988, 8, 766-770.	3.6	147
60	Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology, 2003, 37, 562-567.	3.6	146
61	Three Years of Continuous Entecavir Therapy in Treatment-NaÃ ⁻ ve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. American Journal of Gastroenterology, 2011, 106, 1264-1271.	0.2	145
62	Treatment of chronic hepatitis B: Evolution over two decades. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 138-143.	1.4	143
63	Hepatitis B Virus Core-Related Antigens as Markers for Monitoring Chronic Hepatitis B Infection. Journal of Clinical Microbiology, 2007, 45, 3942-3947.	1.8	139
64	Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology, 2011, 54, 829-836.	3.6	135
65	Hepatitis B virus coreâ€related antigen as a surrogate marker for covalently closed circular DNA. Liver International, 2017, 37, 995-1001.	1.9	132
66	HEPATITIS B VIRUS INFECTION IN CHINESE FAMILIES IN HONGKONG. American Journal of Epidemiology, 1987, 126, 492-499.	1.6	128
67	Expression of c-Myc, c-Fos, and c-Jun in hepatocellular carcinoma. Cancer, 2001, 91, 106-112.	2.0	127
68	Clinicopathological and prognostic significance of serum and tissue <scp>Dickkopfâ€I</scp> levels in human hepatocellular carcinoma. Liver International, 2011, 31, 1494-1504.	1.9	127
69	Molecular Characterization of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus in Paid Blood Donors and Injection Drug Users in China. Journal of Virology, 2004, 78, 13591-13599.	1.5	126
70	Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. Journal of Hepatology, 2017, 66, 275-281.	1.8	126
71	Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 646-653.	1.8	124
72	Hepatitis B and C virus-related carcinogenesis. Clinical Microbiology and Infection, 2009, 15, 964-970.	2.8	123

#	Article	IF	CITATIONS
73	Liver Transplantation in Asian Patients With Chronic Hepatitis B Using Lamivudine Prophylaxis. Annals of Surgery, 2001, 233, 276-281.	2.1	122
74	Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency. Clinical Gastroenterology and Hepatology, 2013, 11, 1004-1010.e1.	2.4	122
75	Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology, 2004, 40, 727-737.	3.6	119
76	Serological markers of liver cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 91-99.	1.0	118
77	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Research, 2015, 121, 97-108.	1.9	116
78	A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut, 2003, 52, 416-419.	6.1	113
79	Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology, 2007, 46, 1695-1703.	3.6	111
80	Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. Biomedicines, 2021, 9, 966.	1.4	111
81	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clinical Microbiology and Infection, 2014, 20, 1173-1180.	2.8	110
82	Oral Nucleoside/Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B. American Journal of Gastroenterology, 2013, 108, 942-948.	0.2	108
83	Chronic Hepatitis B — New Goals, New Treatment. New England Journal of Medicine, 2008, 359, 2488-2491.	13.9	107
84	Molecular Tracing of the Global Hepatitis C Virus Epidemic Predicts Regional Patterns of Hepatocellular Carcinoma Mortality. Gastroenterology, 2006, 130, 703-714.	0.6	106
85	Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Alimentary Pharmacology and Therapeutics, 2006, 24, 1179-1186.	1.9	103
86	PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene, 2004, 23, 4182-4186.	2.6	101
87	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals, 2021, 14, 406.	1.7	101
88	Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B. Gastroenterology, 2014, 146, 138-146.e5.	0.6	99
89	A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology, 2004, 40, 719-726.	3.6	96
90	Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy. Journal of Hepatology, 2009, 50, 289-295.	1.8	96

#	Article	IF	CITATIONS
91	18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clinical Gastroenterology and Hepatology, 2004, 2, 941-945.	2.4	94
92	Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. Clinical and Translational Gastroenterology, 2017, 8, e125.	1.3	93
93	One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels. Antiviral Therapy, 2006, 11, 909-916.	0.6	93
94	Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis, 2004, 25, 1593-1598.	1.3	92
95	Longâ€ŧerm outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. Hepatology, 2017, 66, 1036-1044.	3.6	89
96	Treatment of chronic hepatitis B. Lancet Infectious Diseases, The, 2001, 1, 232-241.	4.6	88
97	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology, 2013, 58, 923-931.	3.6	88
98	Association Between Hepatic Steatosis, Measured by ControlledÂAttenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2018, 16, 575-583.e2.	2.4	86
99	Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology, 2005, 42, 1037-1045.	3.6	85
100	Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 553-559.	1.8	84
101	RNA Interference Therapy With ARCâ€520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. Hepatology, 2020, 72, 19-31.	3.6	84
102	Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection. Clinical Infectious Diseases, 2011, 52, 624-632.	2.9	83
103	Interferon antibodies may negate the antiviral effects of recombinant \hat{I}_{\pm} -interferon treatment in patients with chronic hepatitis B virus infection. Hepatology, 1990, 12, 1266-1270.	3.6	82
104	Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B. Journal of Infectious Diseases, 2011, 203, 646-654.	1.9	82
105	A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology, 2012, 56, 812-819.	3.6	82
106	Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology, 2017, 65, 1451-1461.	3.6	81
107	Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin. Journal of Infectious Diseases, 2008, 198, 808-812.	1.9	80
108	Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antiviral Therapy, 2007, 12, 1295-303.	0.6	78

#	Article	IF	CITATIONS
109	Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver International, 2008, 28, 1408-1416.	1.9	77
110	Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis <scp>B</scp> treatment. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 428-434.	1.4	77
111	Relationship between the Development of Precore and Core Promoter Mutations and Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B Virus. Journal of Infectious Diseases, 2002, 186, 1335-1338.	1.9	76
112	The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. Journal of Viral Hepatitis, 2005, 12, 373-379.	1.0	76
113	Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology, 1999, 29, 1248-1251.	3.6	75
114	Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Alimentary Pharmacology and Therapeutics, 2006, 24, 573-583.	1.9	75
115	Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. Vaccine, 2008, 26, 6587-6591.	1.7	74
116	T1653 Mutation in the Box a Increases the Riskof Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection. Clinical Infectious Diseases, 2006, 42, 1-7.	2.9	73
117	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. Kidney International, 2018, 94, 663-673.	2.6	72
118	High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B. PLoS ONE, 2012, 7, e43087.	1.1	71
119	Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: Identification of 17 novel mutations and its genetic heterogeneity. Journal of Human Genetics, 2008, 53, 55-63.	1.1	69
120	Safety, Tolerability, and Pharmacokinetics of ARCâ€520 Injection, an RNA Interferenceâ€Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2017, 6, 350-362.	0.8	69
121	APPLICABILITY OF LIVING DONOR LIVER TRANSPLANTATION TO HIGH-URGENCY PATIENTS. Transplantation, 1999, 67, 73-77.	0.5	69
122	A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B. PLoS ONE, 2011, 6, e23077.	1.1	69
123	Does the Addition of Endoscopic Sphincterotomy to Stent Insertion Improve Drainage of the Bile Duct in Acute Suppurative Cholangitis?. Gastrointestinal Endoscopy, 2003, 58, 500-504.	0.5	68
124	The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion. American Journal of Gastroenterology, 2009, 104, 1940-1946.	0.2	68
125	Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. Alimentary Pharmacology and Therapeutics, 2003, 17, 289-296.	1.9	67
126	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut, 2014, 63, 996-1004.	6.1	67

#	Article	IF	CITATIONS
127	High prevalence of nonâ€alcoholic fatty liver disease in the Chinese – results from the Hong Kong liver health census. Liver International, 2015, 35, 542-549.	1.9	67
128	Hepatitis B Virus Genotypes B and C Do Not Affect the Antiviral Response to Lamivudine. Antiviral Therapy, 2003, 8, 531-534.	0.6	67
129	Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology, 1999, 29, 924-927.	3.6	66
130	Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology, 2003, 37, 36-43.	3.6	65
131	Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut, 2010, 59, 1389-1393.	6.1	65
132	A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B. PLoS ONE, 2012, 7, e32622.	1.1	65
133	Necrotizing enterocolitis in neonates with symptomatic congenital heart disease. Journal of Pediatrics, 1988, 113, 1044-1049.	0.9	64
134	Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding?. Alimentary Pharmacology and Therapeutics, 2002, 16, 929-936.	1.9	64
135	Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. Journal of Hepatology, 2004, 41, 119-125.	1.8	64
136	Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment. American Journal of Gastroenterology, 2011, 106, 1766-1773.	0.2	62
137	Acuteâ€onâ€chronic liver failure in chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 662-669.	1.4	62
138	Relationship between <scp>HB</scp> sAg, <scp>HB</scp> crAg and hepatocellular carcinoma in patients with undetectable <scp>HBV DNA</scp> under nucleos(t)ide therapy. Journal of Viral Hepatitis, 2017, 24, 654-661.	1.0	62
139	Prostaglandin E1 (Misoprostol) overcomes the adverse effect of chronic cigarette smoking on duodenal ulcer healing. Digestive Diseases and Sciences, 1986, 31, 68S-74S.	1.1	59
140	Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Genotype 6: A Comparison with Genotype 1. Journal of Infectious Diseases, 2003, 187, 1071-1074.	1.9	58
141	Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation, 2003, 76, 1174-1179.	0.5	58
142	HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. Clinical Infectious Diseases, 2013, 56, 1695-1703.	2.9	58
143	Changes of <scp>HBsAg</scp> and <scp>HBV DNA</scp> levels in <scp>C</scp> hinese chronic hepatitis <scp>B</scp> patients after 5 years of entecavir treatment. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1028-1034.	1.4	58
144	Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. American Journal of Gastroenterology, 2016, 111, 1788-1795.	0.2	58

#	Article	IF	CITATIONS
145	Natural history of chronic hepatitis B virus infection. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, E20-E24.	1.4	57
146	Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. Hepatology Research, 2005, 33, 216-24.	1.8	56
147	Genome-Wide Association Study of Hepatocellular Carcinoma in Southern Chinese Patients with Chronic Hepatitis B Virus Infection. PLoS ONE, 2011, 6, e28798.	1.1	56
148	Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses. Hepatology, 1993, 18, 763-767.	3.6	55
149	Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. Journal of Hepatology, 2003, 39, 850-855.	1.8	55
150	Pathogenic role of hepatitis B virus in hepatitis B surface antigen—negative decompensated cirrhosis. Hepatology, 1995, 22, 25-29.	3.6	54
151	Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. Antiviral Research, 2017, 144, 1-7.	1.9	54
152	Acute cholangitis-predictive factors for emergency ERCP. Alimentary Pharmacology and Therapeutics, 2001, 15, 1633-1637.	1.9	52
153	Correlation of Liver Stiffness and Histological Features in Healthy Persons and in Patients With Occult Hepatitis B, Chronic Active Hepatitis B, or Hepatitis B Cirrhosis. American Journal of Gastroenterology, 2010, 105, 1116-1122.	0.2	52
154	Mild-to-Moderate Elevation of Alanine Aminotransferase Increases Liver Stiffness Measurement by Transient Elastography in Patients With Chronic Hepatitis B. American Journal of Gastroenterology, 2011, 106, 492-496.	0.2	52
155	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. Journal of Hepatology, 2013, 59, 709-716.	1.8	52
156	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. Oncotarget, 2015, 6, 34941-34952.	0.8	52
157	Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B. American Journal of Gastroenterology, 2004, 99, 2032-2037.	0.2	51
158	Persistence ofCampylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Digestive Diseases and Sciences, 1987, 32, 1255-1260.	1.1	50
159	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clinical and Translational Gastroenterology, 2017, 8, e116.	1.3	48
160	Longâ€ŧerm outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B eâ€antigen seroclearance. Hepatology, 2018, 68, 462-472.	3.6	48
161	Mirtazapine-Induced Hepatotoxicity. Journal of Clinical Gastroenterology, 2002, 35, 270-271.	1.1	47
162	Prevalence of Fibrosis and Cirrhosis in Chronic Hepatitis B: Implications for Treatment and Management. American Journal of Gastroenterology, 2008, 103, 1421-1426.	0.2	47

#	Article	IF	CITATIONS
163	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3â€year followâ€up study. Journal of Viral Hepatitis, 2011, 18, e200-5.	1.0	47
164	Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. Clinical Gastroenterology and Hepatology, 2020, 18, 449-456.	2.4	47
165	Characterization of interleukin-1β in Helicobacter pylori-induced gastric inflammation and DNA methylation in interleukin-1 receptor type 1 knockout (IL-1R1â^'/â^') mice. European Journal of Cancer, 2013, 49, 2760-2770.	1.3	46
166	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. Journal of Hepatology, 2015, 62, 526-532.	1.8	46
167	Profound suppression of hepatitis B virus replication with lamivudine. Journal of Medical Virology, 2000, 61, 367-373.	2.5	45
168	Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Annals of Oncology, 2003, 14, 1463-1467.	0.6	45
169	Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology, 2010, 51, 1185-1189.	3.6	45
170	Significance of isolated anti-HBc seropositivity by ELISA: Implications and the role of radioimmunoassay. Journal of Medical Virology, 1992, 36, 180-183.	2.5	44
171	Transcatheter Arterial Chemoembolization in Inoperable Hepatocellular Carcinoma: Four-year Follow-up. Journal of Vascular and Interventional Radiology, 1996, 7, 419-425.	0.2	44
172	Prognostic Factors in Severe Exacerbation of Chronic Hepatitis B. Clinical Infectious Diseases, 2003, 36, 979-984.	2.9	44
173	Overestimation of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera. Hepatology, 1991, 14, 756-762.	3.6	43
174	Hepatocellular carcinoma in chinese males and females. Possible causes for the male predominance. Cancer, 1987, 60, 1107-1110.	2.0	42
175	Transarterial Chemoembolization for Inoperable, Early Stage Hepatocellular Carcinoma in Patients With Child-Pugh Grade A and B: Results of A Comparative Study in 96 Chinese Patients. American Journal of Gastroenterology, 2003, 98, 1181-1185.	0.2	42
176	Hepatitis B Virus with Primary Resistance to Adefovir. New England Journal of Medicine, 2006, 355, 322-323.	13.9	42
177	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. Journal of Viral Hepatitis, 2011, 18, 738-744.	1.0	42
178	Chronic Hepatitis B Virus Infection. Journal of Clinical Gastroenterology, 2016, 50, 286-294.	1.1	42
179	Role of HLA-DP Polymorphisms on Chronicity and Disease Activity of Hepatitis B Infection in Southern Chinese. PLoS ONE, 2013, 8, e66920.	1.1	42
180	Pharmacokinetics of Telbivudine following Oral Administration of Escalating Single and Multiple Doses in Patients with Chronic Hepatitis B Virus Infection: Pharmacodynamic Implications. Antimicrobial Agents and Chemotherapy, 2006, 50, 874-879.	1.4	40

#	Article	IF	CITATIONS
181	Fibrosis evolution in chronic hepatitis B e antigenâ€negative patients across a 10â€year interval. Journal of Viral Hepatitis, 2019, 26, 818-827.	1.0	40
182	Adefovir Dipivoxil Monotherapy and Combination Therapy with Lamivudine for the Treatment of Chronic Hepatitis B in an Asian Population. Antiviral Therapy, 2007, 12, 41-46.	0.6	40
183	A Randomized Placebo-Controlled, Dose-Finding Study of Oral Lb80380 in Hbeag-Positive Patients with Chronic Hepatitis B. Antiviral Therapy, 2006, 11, 977-984.	0.6	40
184	Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection. American Journal of Gastroenterology, 2005, 100, 1099-1103.	0.2	39
185	Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology, 2010, 51, 767-776.	3.6	39
186	Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. World Journal of Gastroenterology, 2017, 23, 7716-7726.	1.4	39
187	Factors influencing healing of duodenal ulcer. Digestive Diseases and Sciences, 1985, 30, 45-51.	1.1	38
188	Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation, 2003, 75, S41-S44.	0.5	38
189	Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection. World Journal of Gastroenterology, 2009, 15, 3288.	1.4	38
190	Defining Normal Liver Stiffness Range in a Normal Healthy Chinese Population without Liver Disease. PLoS ONE, 2013, 8, e85067.	1.1	38
191	Current seroepidemiology of hepatitis A in Hong Kong. Journal of Medical Virology, 1991, 34, 191-193.	2.5	37
192	A randomised controlled trial of endoscopic sphincterotomy in acute cholangitis without common bile duct stones. Gut, 2002, 51, 245-247.	6.1	37
193	Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation. Clinical Infectious Diseases, 2003, 37, 593-597.	2.9	37
194	Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. Cancer Letters, 2017, 403, 330-338.	3.2	37
195	Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. Journal of Viral Hepatitis, 2007, 14, 269-275.	1.0	36
196	Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infectious Diseases, The, 2009, 9, 256-264.	4.6	36
197	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World Journal of Gastroenterology, 2013, 19, 8887.	1.4	36
198	Real-Time PCR Assay Using Molecular Beacon for Quantitation of Hepatitis B Virus DNA. Journal of Clinical Microbiology, 2004, 42, 3438-3440.	1.8	35

#	Article	lF	CITATIONS
199	Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. Journal of Hepatology, 2010, 53, 444-448.	1.8	35
200	Chronic Antral Gastritis in Duodenal Ulcer. Gastroenterology, 1986, 91, 1095-1101.	0.6	34
201	Longitudinal Study of Hepatitis Activity and Viral Replication before and after HBeAg Seroconversion in Chronic Hepatitis B Patients Infected with Genotypes B and C. Journal of Clinical Microbiology, 2004, 42, 5036-5040.	1.8	34
202	Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case–control study. Alimentary Pharmacology and Therapeutics, 2007, 26, 377-382.	1.9	34
203	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatology International, 2013, 7, 98-105.	1.9	34
204	Hepatitis B core protein as a therapeutic target. Expert Opinion on Therapeutic Targets, 2017, 21, 1153-1159.	1.5	34
205	Response to Combined Interferon and Ribavirin Is Better in Patients Infected with Hepatitis C Virus Genotype 6 than Genotype 1 in Hong Kong. Intervirology, 2006, 49, 96-98.	1.2	33
206	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. Journal of Hepatology, 2011, 55, 522-528.	1.8	33
207	Bodyâ€mass index is associated with fibrosis regression during longâ€ŧerm nucleoside analogue therapy in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2016, 44, 1071-1079.	1.9	33
208	Ketamine-Induced Cholangiopathy: A Case Report. American Journal of Gastroenterology, 2011, 106, 1004-1005.	0.2	32
209	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. Journal of Infectious Diseases, 2019, 219, 1924-1933.	1.9	32
210	Nucleic Acid-Based Cross-Linking Assay for Detection and Quantification of Hepatitis B Virus DNA. Journal of Clinical Microbiology, 1999, 37, 161-164.	1.8	32
211	One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antiviral Therapy, 2006, 11, 909-16.	0.6	32
212	Low Molecular Weight Heparin-Induced Liver Toxicity. Journal of Clinical Pharmacology, 2001, 41, 691-694.	1.0	31
213	Hbsag seroclearance in the natural history of chronic hepatitis b infection. Current Hepatitis Reports, 2006, 5, 23-26.	0.3	31
214	Mechanism of Entecavir Resistance of Hepatitis B Virus with Viral Breakthrough as Determined by Long-Term Clinical Assessment and Molecular Docking Simulation. Antimicrobial Agents and Chemotherapy, 2010, 54, 882-889.	1.4	31
215	Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis E antigen seroconversion. Journal of Hepatology, 2004, 40, 1008-1017.	1.8	30
216	Use of Liver Stiffness Measurement for Liver Resection Surgery: Correlation with Indocyanine Green Clearance Testing and Post-Operative Outcome. PLoS ONE, 2013, 8, e72306.	1.1	30

#	Article	IF	CITATIONS
217	Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. Alimentary Pharmacology and Therapeutics, 2017, 45, 501-509.	1.9	30
218	An oligonucleotide probe for the detection of hepatitis B virus DNA in serum. Journal of Virological Methods, 1987, 15, 139-149.	1.0	29
219	Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. Hepatology International, 2010, 4, 716-722.	1.9	29
220	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy. Journal of Hepatology, 2011, 54, 195-200.	1.8	29
221	Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA. JHEP Reports, 2020, 2, 100112.	2.6	29
222	Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. Oncotarget, 2017, 8, 47507-47517.	0.8	29
223	Factors determining the development of hepatocellular carcinoma in hepatitis b surface antigen carriers. A comparison between families with clusters and solitary cases. Cancer, 1988, 61, 1287-1291.	2.0	28
224	Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: Successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transplantation, 2004, 10, 557-563.	1.3	28
225	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. Journal of Gastroenterology, 2016, 51, 487-495.	2.3	28
226	Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. Journal of Clinical Microbiology, 2007, 45, 3935-3941.	1.8	27
227	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. Vaccines, 2021, 9, 1097.	2.1	27
228	Interferon therapy of chronic hepatitis B virus infection in Chinese. Journal of Hepatology, 1986, 3, S209-S215.	1.8	26
229	Acute pancreatitis complicating acute exacerbation of chronic hepatitis B infection carries a poor prognosis. Journal of Viral Hepatitis, 2001, 8, 459-464.	1.0	26
230	Interleukin-1Î ² increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. Oncology Letters, 2016, 11, 2919-2924.	0.8	26
231	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Alimentary Pharmacology and Therapeutics, 2016, 43, 96-101.	1.9	26
232	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clinical and Translational Gastroenterology, 2018, 9, e163.	1.3	26
233	CLINICOPATHOLOGIC FEATURES OF HEPATITIS C VIRUS INFECTION IN RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1994, 58, 996-1000.	0.5	25
234	Hepatic Expression of Hepatitis B Virus Genome in Chronic Hepatitis B Virus Infection. American Journal of Clinical Pathology, 1996, 105, 87-95.	0.4	25

#	Article	IF	CITATIONS
235	Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver International, 1999, 19, 444-451.	1.9	25
236	Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Alimentary Pharmacology and Therapeutics, 2005, 21, 841-849.	1.9	25
237	Safety evaluation of telbivudine. Expert Opinion on Drug Safety, 2010, 9, 821-829.	1.0	25
238	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Current Hepatitis Reports, 2011, 10, 235-243.	0.3	25
239	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut, 2022, 71, 789-797.	6.1	25
240	Hepatitis B Genotypes in Chronic Hepatitis B and Lamivudine Therapy. Intervirology, 2003, 46, 373-376.	1.2	24
241	Combination Therapy for Chronic Hepatitis B: Simultaneous or Sequential?. American Journal of Gastroenterology, 2007, 102, 105-106.	0.2	24
242	Etiologies of chronic liver diseases in Hong Kong. European Journal of Gastroenterology and Hepatology, 2007, 19, 659-664.	0.8	24
243	Role of <scp>IL</scp> 28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. Journal of Viral Hepatitis, 2013, 20, 470-477.	1.0	24
244	Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. Journal of Viral Hepatitis, 2005, 12, 513-518.	1.0	23
245	New paradigms for the treatment of chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1182-1192.	1.4	23
246	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. Clinical and Translational Gastroenterology, 2017, 8, e100.	1.3	23
247	HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection. Journal of Clinical Microbiology, 2004, 42, 4882-4884.	1.8	22
248	LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs, 2008, 17, 1581-1588.	1.9	22
249	DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 383-392.	1.0	22
250	Hepatitis B coreâ€related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. Journal of Viral Hepatitis, 2019, 26, 1473-1480.	1.0	22
251	Detection of Intrahepatic Hepatitis B Virus DNA and Correlation with Hepatic Necroinflammation and Fibrosis. Journal of Clinical Microbiology, 2004, 42, 3920-3924.	1.8	21
252	Adefovir dipivoxil in chronic hepatitis B infection. Expert Opinion on Pharmacotherapy, 2004, 5, 2361-2367.	0.9	21

#	Article	IF	CITATIONS
253	Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. Antimicrobial Agents and Chemotherapy, 2009, 53, 1779-1785.	1.4	21
254	Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. Liver Transplantation, 2015, 21, 1504-1510.	1.3	21
255	Significance of Viral Load, Core Promoter/Precore Mutations and Specific Sequences of Polymerase Gene in Hbv-Infected Patients on 3-Year Lamivudine Treatment. Antiviral Therapy, 2006, 11, 779-786.	0.6	21
256	The hepatitis C virus genome: a guide to its conserved sequences and candidate epitopes. Virus Research, 1993, 30, 27-41.	1.1	20
257	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. Annals of Internal Medicine, 2019, 171, 496.	2.0	20
258	Absence of transmission of hepatitis B by fibreoptic upper gastrointestinal endoscopy. Journal of Gastroenterology and Hepatology (Australia), 1987, 2, 175-180.	1.4	19
259	Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapy. Journal of Medical Virology, 2002, 67, 334-338.	2.5	19
260	Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Review of Anti-Infective Therapy, 2010, 8, 717-726.	2.0	19
261	Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis. American Journal of Gastroenterology, 2014, 109, 1764-1770.	0.2	19
262	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0148493.	1.1	19
263	Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatology International, 2016, 10, 407-414.	1.9	19
264	Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). Journal of Hepatology, 2004, 41, 686-687.	1.8	18
265	Outcome of Lamivudine-Resistant Chronic Hepatitis B after up to 5 Years of Combination Therapy with Adefovir. Antiviral Therapy, 2012, 17, 1255-1262.	0.6	18
266	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir. Antiviral Therapy, 2013, 18, 691-698.	0.6	18
267	HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. Scientific Reports, 2020, 10, 802.	1.6	18
268	Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus–related chronic liver diseases. Hepatology, 1991, 13, 834-837.	3.6	17
269	The Role of Steatosis in HBsAg Seroclearance for Patients with Chronic Hepatitis B Infection: Fact or Fiction?. Digestive Diseases and Sciences, 2013, 58, 20-22.	1.1	17
270	The effect of interferonâ€free regimens on healthâ€related quality of life in East Asian patients with chronic hepatitis C. Liver International, 2018, 38, 1179-1187.	1.9	17

#	Article	IF	CITATIONS
271	Comparison of the COBAS TaqManâ,,¢ HBV test with the COBAS Amplicor monitorâ,,¢ test for measurement of hepatitis B virus DNA in serum. Journal of Medical Virology, 2005, 77, 486-490.	2.5	16
272	Realâ€life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1230-1233.	1.4	16
273	A large realâ€world cohort study examining the effects of longâ€ŧerm entecavir on hepatocellular carcinoma and HBsAg seroclearance. Journal of Viral Hepatitis, 2020, 27, 397-406.	1.0	16
274	Management of chronic hepatitis B in severe liver disease. World Journal of Gastroenterology, 2014, 20, 16053.	1.4	16
275	A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antiviral Therapy, 2006, 11, 977-83.	0.6	16
276	Pathogenetic role of Campylobacter pyloridis in gastric ulcer. Journal of Gastroenterology and Hepatology (Australia), 1987, 2, 309-316.	1.4	15
277	Relationship Between Intrahepatic Expression of Hepatitis B Viral Antigens and Histology in Chinese Patients With Chronic Hepatitis B Virus Infection. American Journal of Clinical Pathology, 1993, 100, 648-653.	0.4	15
278	Intestinal tuberculosis mimicking fistulizing Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 137-139.	1.4	15
279	The Effects of IL-28B and ITPA Polymorphisms on Treatment of Hepatitis C Virus Genotype 6. American Journal of Gastroenterology, 2011, 106, 1007-1008.	0.2	15
280	Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection. PLoS ONE, 2014, 9, e99028.	1.1	15
281	Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antiviral Therapy, 2007, 12, 41-6.	0.6	15
282	Synergism of chronic alcoholism and hepatitis B infection in liver disease. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 11-16.	1.4	14
283	Antiviral therapy for hepatitis B and C in Asians. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, S19-S21.	1.4	14
284	Cholangiocarcinoma in liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 337-341.	1.4	14
285	Long-Term Follow-Up Study of Chinese Patients with YMDD Mutations: Significance of Hepatitis B Virus Genotypes and Characteristics of Biochemical Flares. Journal of Clinical Microbiology, 2004, 42, 3932-3936.	1.8	14
286	Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: Six-hour versus overnight observation. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1163-1168.	1.4	14
287	Hepatitis B virus genotypes: natural history and implications for treatment. Expert Review of Gastroenterology and Hepatology, 2007, 1, 321-328.	1.4	14
288	The use of transient elastography in the management of chronic hepatitis B. Hepatology International, 2011, 5, 868-875.	1.9	14

#	Article	IF	CITATIONS
289	High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2012, 10, 1047-1050.e1.	2.4	14
290	Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. Journal of Gastroenterology, 2017, 52, 1064-1074.	2.3	14
291	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney International Reports, 2020, 5, 1129-1138.	0.4	14
292	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World Journal of Gastroenterology, 2019, 25, 1398-1408.	1.4	14
293	Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. Transplantation Proceedings, 1999, 31, 535-536.	0.3	13
294	A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer, 2003, 97, 2776-2782.	2.0	13
295	The Role of Cholecystectomy in Reducing Recurrent Gallstone Pancreatitis. Endoscopy, 2004, 36, 206-211.	1.0	13
296	A case–control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatology Research, 2006, 35, 127-134.	1.8	13
297	Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0139478.	1.1	13
298	Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer. Digestive Diseases and Sciences, 1989, 34, 1494-1500.	1.1	12
299	Clinical Evaluation of the Digene Hybrid Capture II Test and the COBAS AMPLICOR Monitor Test for Determination of Hepatitis B Virus DNA Levels. Journal of Clinical Microbiology, 2004, 42, 3513-3517.	1.8	12
300	Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. Journal of Infection, 2007, 54, 497-503.	1.7	12
301	Mutational analysis for Wilson's disease. Lancet, The, 2009, 374, 662.	6.3	12
302	Profile of pre‣ deletions in the natural history of chronic hepatitis B infection. Journal of Medical Virology, 2010, 82, 1843-1849.	2.5	12
303	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years. Hepatology, 2011, 53, 1148-1153.	3.6	12
304	Application of Coamplification at Lower Denaturation Temperature-PCR Sequencing for Early Detection of Antiviral Drug Resistance Mutations of Hepatitis B Virus. Journal of Clinical Microbiology, 2014, 52, 3209-3215.	1.8	12
305	HBV research moves forward—receptors and reactivation. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 70-72.	8.2	12
306	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatology International, 2019, 13, 148-156.	1.9	12

#	Article	IF	CITATIONS
307	Serum Macâ€2â€binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavirâ€treated chronic hepatitis B patients. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1817-1823.	1.4	12
308	Case report of symptomatic porphyria cutanea tarda associated with histiocytic lymphoma. Cancer, 1984, 53, 573-576.	2.0	11
309	Systemic corticosteroid and reactivation of chronic hepatitis B. Respirology, 2010, 15, 1017-1018.	1.3	11
310	Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Hepatology International, 2013, 7, 119-126.	1.9	11
311	Hepatitis B: treatment choice and monitoring for response and resistance. Expert Review of Gastroenterology and Hepatology, 2016, 10, 697-707.	1.4	11
312	Clinical efficacy of lenvatinib for the treatment of radioiodineâ€refractory thyroid carcinoma: A systematic review and metaâ€analysis of clinical trials. Clinical Endocrinology, 2021, 95, 478-488.	1.2	11
313	Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology, 1993, 17, 389-394.	3.6	11
314	Role of cholecystectomy in preventing recurrent cholangitis. Gastrointestinal Endoscopy, 2002, 56, 55-60.	0.5	10
315	Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Current Hepatitis Reports, 2011, 10, 106-111.	0.3	10
316	Effect of Hepatitis B Virus Reverse Transcriptase Variations on Entecavir Treatment Response. Journal of Infectious Diseases, 2014, 210, 701-707.	1.9	10
317	Hepatitis B virus fullâ€length genomic mutations and quasispecies in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1638-1645.	1.4	10
318	Reversal of Protein-Losing Enteropathy by Liver Transplantation. Journal of Clinical Gastroenterology, 2003, 36, 86-87.	1.1	10
319	Stanniocalcin 1 is a serum biomarker and potential therapeutic target for HBV â€associated liver fibrosis. Journal of Pathology, 2022, , .	2.1	10
320	Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. Journal of Hepatology, 1992, 14, 332-334.	1.8	9
321	Current and future antiviral agents for chronic hepatitis B. Journal of Antimicrobial Chemotherapy, 2003, 51, 481-485.	1.3	9
322	Telbivudine: an upcoming agent for chronic hepatitis B. Expert Review of Anti-Infective Therapy, 2005, 3, 489-494.	2.0	9
323	Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: reâ€evaluation of <scp>HB</scp> sAg seroclearance. Liver International, 2016, 36, 642-650.	1.9	9
324	Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance. PLoS ONE, 2014, 9, e99422.	1.1	9

#	Article	IF	CITATIONS
325	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antiviral Therapy, 2009, 14, 679-685.	0.6	9
326	Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2005, 22, 301-307.	1.9	8
327	Emerging drugs for the treatment of hepatitis B. Expert Opinion on Emerging Drugs, 2016, 21, 183-193.	1.0	8
328	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 483-491.	1.5	8
329	Model for End‣tage Liver Disease With Additional Criteria to Predict Shortâ€Term Mortality in Severe Flares of Chronic Hepatitis B. Hepatology, 2020, 72, 818-828.	3.6	8
330	Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antiviral Therapy, 2006, 11, 779-86.	0.6	8
331	Stability of hepatitis B surface antigen over time: Implications for studies using stored sera. Journal of Medical Virology, 2011, 83, 1900-1904.	2.5	7
332	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. Clinical Gastroenterology and Hepatology, 2019, 17, 1410-1412.	2.4	7
333	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. World Journal of Gastroenterology, 2017, 23, 7863-7874.	1.4	7
334	Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. Alimentary Pharmacology and Therapeutics, 2004, 19, 401-406.	1.9	6
335	Determinants for the Occurrence of Acute Exacerbation of Hepatitis B Virus Infection in Chinese Patients after HBeAg Seroclearance. Journal of Clinical Microbiology, 2005, 43, 1594-1599.	1.8	6
336	Hepatitis B surface antigen levels after hepatitis B eâ€antigen seroclearance: a longitudinal followâ€up study. Liver International, 2015, 35, 854-859.	1.9	6
337	Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. Transplantation, 2017, 101, 2391-2398.	0.5	6
338	A comprehensive HBV array for the detection of HBV mutants and genotype. Clinical Biochemistry, 2011, 44, 1253-1260.	0.8	5
339	Future Prevention and Treatment of Chronic Hepatitis B Infection. Journal of Clinical Gastroenterology, 2012, 46, 725-734.	1.1	5
340	Factors for Hepatitis B vaccination and Abnormal Liver Function in Chinese Patients with Inflammatory Bowel Disease: A Single Center Experience. Journal of Digestive Diseases, 2013, 14, n/a-n/a.	0.7	5
341	The role of interleukinâ€⊋7 in predicting spontaneous <scp>HB</scp> eAg seroconversion in chronic hepatitis B infection. Liver International, 2017, 37, 1287-1294.	1.9	5
342	<scp>HLA</scp> â€ <scp>DP</scp> and γâ€interferon receptorâ€2 gene variants and their association with viral hepatitis activity in chronic hepatitis <scp>B</scp> infection. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 533-539.	1.4	4

#	Article	IF	CITATIONS
343	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 101-106.	1.5	4
344	Deferred treatment with a fixedâ€dose combination of sofosbuvirâ€velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection. Journal of Viral Hepatitis, 2019, 26, 1229-1232.	1.0	4
345	Measuring and Validating a General Cancer Predisposition Perception Scale: An Adaptation of the Revised-IPQ-Genetic Predisposition Scale. PLoS ONE, 2015, 10, e0142620.	1.1	4
346	Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology, 1995, 22, 25-29.	3.6	3
347	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B results of a comparative study in 96 Chinese patients. American Journal of Gastroenterology, 2003, 98, 1181-1185.	0.2	3
348	Prediction of treatment outcomes for lamivudine. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 964-965.	1.4	3
349	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatology International, 2013, 7, 327-334.	1.9	3
350	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. Journal of Infectious Diseases, 2019, 220, 940-950.	1.9	3
351	L-dT: An ongoing phase I/IIa dose-escalation trial in patients with chronic HBV infection (NV-02B-001). Gastroenterology, 2001, 120, A572.	0.6	2
352	Recombinant Interferon Alfa 2b Therapy in a Patient With Metastatic Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2002, 35, 272-275.	1.1	2
353	Specific Considerations in the Design of Hepatitis B Virus Clinical Studies in the Far East. , 2004, 96, 457-464.		2
354	Overcoming the problem of chronic hepatitis B. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 197-202.	0.5	2
355	Telbivudine for chronic hepatitisÂB: the GLOBE trial. Future Virology, 2008, 3, 317-323.	0.9	2
356	The saga of entecavir. Hepatology International, 2009, 3, 421-424.	1.9	2
357	To stop or not to stop: The quest for longâ€ŧerm viral suppression. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 420-422.	1.4	2
358	Management of Chronic Hepatitis B in Patients from Special Populations. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a021527-a021527.	2.9	2
359	Serum ceruloplasmin monitoring in a case of silver intoxication due to intravenous silver infusion. Clinical Toxicology, 2022, 60, 255-258.	0.8	2
360	Treatment of Chronic Hepatitis C with Different Genotypes. , 2008, , 130-147.		2

#	Article	IF	CITATIONS
361	Prevalence and significance of hepatitis GB virus-c/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. Digestive Diseases and Sciences, 2002, 47, 432-437.	1.1	1
362	Treatment for Hepatitis B. Journal of Clinical Gastroenterology, 2004, 38, S134-S135.	1.1	1
363	What Is the Best End Point for Hepatitis B Treatment?. Annals of Internal Medicine, 2008, 148, 560.	2.0	1
364	471 HBV DNA Levels Predict Significant Liver Histology for HBeAg-Negative Chronic Hepatitis B Patients. Gastroenterology, 2010, 138, S-788.	0.6	1
365	Reply to Liao et al. Clinical Infectious Diseases, 2013, 57, 622-622.	2.9	1
366	Reply:. Hepatology, 2013, 58, 1857-1857.	3.6	1
367	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. Digestive Diseases and Sciences, 2019, 64, 3630-3641.	1.1	1
368	Memoir on hepatitis and liver disease history in Hong Kong. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S510-S510.	1.4	0
369	Entecavir. Drugs, 2006, 66, 1623-1624.	4.9	0
370	Recommendations and potential future options in the treatment of hepatitis B. Expert Opinion on Pharmacotherapy, 2006, 7, 2225-2231.	0.9	0
371	Acute Hepatitis as a Presentation of Acute Appendicitis in an Immunocompromised Patient. Journal of Clinical Gastroenterology, 2002, 35, 203-204.	1.1	0
372	Clinical experience and follow-up with lamivudine in the Asian population. , 2003, , 383-390.		0
373	New Antiviral Treatment for Chronic Hepatitis B. , 2004, , 47-56.		0
374	Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?. Hepatobiliary Surgery and Nutrition, 2013, 2, 34-6.	0.7	0